These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

812 related items for PubMed ID: 30420622

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Residual Inflammatory Risk on Treatment With PCSK9 Inhibition and Statin Therapy.
    Pradhan AD, Aday AW, Rose LM, Ridker PM.
    Circulation; 2018 Jul 10; 138(2):141-149. PubMed ID: 29716940
    [Abstract] [Full Text] [Related]

  • 3. Associations between lower levels of low-density lipoprotein cholesterol and cardiovascular events in very high-risk patients: Pooled analysis of nine ODYSSEY trials of alirocumab versus control.
    Vallejo-Vaz AJ, Ray KK, Ginsberg HN, Davidson MH, Eckel RH, Lee LV, Bessac L, Pordy R, Letierce A, Cannon CP.
    Atherosclerosis; 2019 Sep 10; 288():85-93. PubMed ID: 31349086
    [Abstract] [Full Text] [Related]

  • 4. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons.
    Yadav K, Sharma M, Ferdinand KC.
    Nutr Metab Cardiovasc Dis; 2016 Oct 10; 26(10):853-62. PubMed ID: 27352986
    [Abstract] [Full Text] [Related]

  • 5. Pleiotropic Effects of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibitors?
    Bittner V.
    Circulation; 2016 Nov 29; 134(22):1695-1696. PubMed ID: 27895023
    [No Abstract] [Full Text] [Related]

  • 6. How much should LDL cholesterol be lowered in secondary prevention? Clinical efficacy and safety in the era of PCSK9 inhibitors.
    Cybulska B, Kłosiewicz-Latoszek L, Penson PE, Nabavi SM, Lavie CJ, Banach M, International Lipid Expert Panel (ILEP).
    Prog Cardiovasc Dis; 2021 Nov 29; 67():65-74. PubMed ID: 33383060
    [Abstract] [Full Text] [Related]

  • 7. Lipoprotein(a) reductions from PCSK9 inhibition and major adverse cardiovascular events: Pooled analysis of alirocumab phase 3 trials.
    Ray KK, Vallejo-Vaz AJ, Ginsberg HN, Davidson MH, Louie MJ, Bujas-Bobanovic M, Minini P, Eckel RH, Cannon CP.
    Atherosclerosis; 2019 Sep 29; 288():194-202. PubMed ID: 31253441
    [Abstract] [Full Text] [Related]

  • 8. PCSK9 inhibition 2018: riding a new wave of coronary prevention.
    Ward NC, Page MM, Watts GF.
    Clin Sci (Lond); 2019 Jan 31; 133(2):205-224. PubMed ID: 30670671
    [Abstract] [Full Text] [Related]

  • 9. PCSK9 inhibition and inflammation: A narrative review.
    Ruscica M, Tokgözoğlu L, Corsini A, Sirtori CR.
    Atherosclerosis; 2019 Sep 31; 288():146-155. PubMed ID: 31404822
    [Abstract] [Full Text] [Related]

  • 10. PCSK9 Inhibitors in Secondary Prevention-An Opportunity for Personalized Therapy.
    Board C, Kelly MS, Shapiro MD, Dixon DL.
    J Cardiovasc Pharmacol; 2020 May 31; 75(5):410-420. PubMed ID: 32379108
    [Abstract] [Full Text] [Related]

  • 11. Treatment with PCSK9 inhibitors reduces atherogenic VLDL remnants in a real-world study.
    Hollstein T, Vogt A, Grenkowitz T, Stojakovic T, März W, Laufs U, Bölükbasi B, Steinhagen-Thiessen E, Scharnagl H, Kassner U.
    Vascul Pharmacol; 2019 May 31; 116():8-15. PubMed ID: 30910670
    [Abstract] [Full Text] [Related]

  • 12. Alirocumab as add-on therapy to statins: current evidence and clinical potential.
    Auer J, Berent R.
    Ther Adv Cardiovasc Dis; 2018 Jul 31; 12(7):191-202. PubMed ID: 29792380
    [Abstract] [Full Text] [Related]

  • 13. Lipid management in ACS: Should we go lower faster?
    Gencer B, Mach F.
    Atherosclerosis; 2018 Aug 31; 275():368-375. PubMed ID: 30015301
    [Abstract] [Full Text] [Related]

  • 14. A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular outcomes.
    Khan SU, Talluri S, Riaz H, Rahman H, Nasir F, Bin Riaz I, Sattur S, Ahmed H, Kaluski E, Krasuski R.
    Eur J Prev Cardiol; 2018 May 31; 25(8):844-853. PubMed ID: 29569492
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. PCSK9 inhibition for LDL lowering and beyond - implications for patients with peripheral artery disease.
    Gebauer K, Reinecke H.
    Vasa; 2018 Apr 31; 47(3):165-176. PubMed ID: 29412075
    [Abstract] [Full Text] [Related]

  • 17. Metformin-Induced Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition Further Decreases Low-Density Lipoprotein Cholesterol Following Statin Treatment in Patients With Coronary Artery Disease and Without Diabetes.
    Hu D, Qin D, Kuang J, Yang Y, Weng S, Chen J, Wu S, Wang S, Mao L, Peng D, Yu B.
    J Cardiovasc Pharmacol; 2024 Aug 01; 84(2):261-269. PubMed ID: 38922587
    [Abstract] [Full Text] [Related]

  • 18. Peripheral Artery Disease and Venous Thromboembolic Events After Acute Coronary Syndrome: Role of Lipoprotein(a) and Modification by Alirocumab: Prespecified Analysis of the ODYSSEY OUTCOMES Randomized Clinical Trial.
    Schwartz GG, Steg PG, Szarek M, Bittner VA, Diaz R, Goodman SG, Kim YU, Jukema JW, Pordy R, Roe MT, White HD, Bhatt DL, ODYSSEY OUTCOMES Committees and Investigators*.
    Circulation; 2020 May 19; 141(20):1608-1617. PubMed ID: 32223446
    [Abstract] [Full Text] [Related]

  • 19. The efficacy of anti-PCSK9 antibodies: Results from recent trials.
    Gouni-Berthold I.
    Atheroscler Suppl; 2017 Nov 19; 30():9-18. PubMed ID: 29096867
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 41.